In clinical trials of ICI drugs for TNBC, the positive rate of PD-L1 expression status in tumor cells or immune cells ranged from 19.4% to 68%, and the overall response rate to ICI drugs was 5% to 42% (62, 101–106). Here, CD274 is linked to neoplasm.